Amita Shukla-Dave1, Cecilia Wassberg2, Darko Pucar3, Heiko Schoder1, Debra Goldman1, Victor E. Reuter1, James Eastham1, Peter T. Scardino1, Steve M. Larson1, Hedvig Hricak1
1Memorial Sloan-Kettering Cancer Center, New York, United States; 2Uppsala University Hospital, Uppsala, Sweden; 3Georgia Health Sciences University, Augusta, GA, United States
Although metabolic imaging is frequently performed in cancer patients, the underlying genomic and biochemical mechanisms and the consequent imaging findings remain poorly understood. The purpose of this study was to evaluate citrate metabolism and glucose consumption in prostate cancer (PCa) using 1H-MRSI and 18F-FDG PET. Whole mount step section pathology was used as the standard of reference. Clinical, 1H-MRSI, 18F-FDG PET data were examined in 22 patients. 1H-MRSI was better able to detect index tumors in 21 patients while 18F-FDG PET detected tumor in 3 patients. Thus, we suggest that altered citrate metabolism precedes increased glucose consumption in PCa.